Published in Nat Rev Drug Discov on August 01, 2004
Matching Patients With Hematologic Malignancy to Adequate Clinical Trials | NCT02758080
Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO) | NCT02078544
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69
Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov (2012) 5.55
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med (2011) 3.80
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol (2012) 3.65
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov (2014) 2.98
Validating therapeutic targets through human genetics. Nat Rev Drug Discov (2013) 2.94
A network view of disease and compound screening. Nat Rev Drug Discov (2009) 2.90
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Toxicology for the twenty-first century. Nature (2009) 2.81
The future of drug development: advancing clinical trial design. Nat Rev Drug Discov (2009) 2.68
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov (2011) 2.12
Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol (2012) 2.11
Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron (2015) 2.09
Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst (2008) 2.08
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol (2010) 2.07
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci (2010) 2.06
Why primate models matter. Am J Primatol (2014) 2.05
Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol (2010) 1.97
Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov (2015) 1.95
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem (2008) 1.94
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med (2013) 1.92
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Developing predictive molecular maps of human disease through community-based modeling. Nat Genet (2012) 1.88
Designing phase 0 cancer clinical trials. Clin Cancer Res (2008) 1.85
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol (2010) 1.77
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
The relevance and potential roles of microphysiological systems in biology and medicine. Exp Biol Med (Maywood) (2014) 1.74
Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing. Nat Biotechnol (2014) 1.72
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 1.70
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch Toxicol (2011) 1.69
PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res (2010) 1.69
Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci (2010) 1.66
An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov (2015) 1.62
Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J (2005) 1.59
Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov (2008) 1.59
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med (2011) 1.52
Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol (2014) 1.52
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov (2014) 1.51
Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip (2013) 1.50
Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv (2015) 1.49
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Pathway reporter genes define molecular phenotypes of human cells. BMC Genomics (2015) 1.43
A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci Transl Med (2015) 1.43
The potential of high-content high-throughput microscopy in drug discovery. Br J Pharmacol (2007) 1.42
Merging systems biology with pharmacodynamics. Sci Transl Med (2012) 1.39
The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev (2011) 1.39
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood (2010) 1.33
Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv (2014) 1.33
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology (2010) 1.30
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol (2013) 1.30
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol (2014) 1.30
Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther (2011) 1.28
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J (2008) 1.27
Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res (2010) 1.27
Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med (2013) 1.27
Pharmacogenomics, evidence, and the role of payers. Public Health Genomics (2009) 1.26
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact (2006) 1.26
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A (2011) 1.26
The impact of anxiety upon cognition: perspectives from human threat of shock studies. Front Hum Neurosci (2013) 1.25
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Drug repositioning for personalized medicine. Genome Med (2012) 1.24
Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market. Daru (2014) 1.23
Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J (2006) 1.23
Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J Med Chem (2009) 1.23
Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Mol Syst Biol (2013) 1.22
Predicting adverse side effects of drugs. BMC Genomics (2011) 1.22
Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res (2013) 1.22
Metrics for antibody therapeutics development. MAbs (2010) 1.21
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19
Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen (2010) 1.18
Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Mov Disord (2009) 1.18
Network neighbors of drug targets contribute to drug side-effect similarity. PLoS One (2011) 1.17
Stability of IgG isotypes in serum. MAbs (2010) 1.17
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer (2007) 1.17
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst (2011) 1.17
SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res (2014) 1.14
A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clin Cancer Res (2012) 1.14
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One (2012) 1.14
Should preclinical studies be registered? Nat Biotechnol (2012) 1.14